Swedish Orphan Biovitrum AB (publ) (Sobi) has been awarded the Company of the Year Award at the European Mediscience Awards 2014.
Companies that have gained recognition from analysts and investors for management, financial stability and growth with a well-defined strategy to deliver its key financial, ethical and social ambitions are in contention to receive the prize.
“Sobi is truly honoured to be recognised by the Mediscience community”, said Geoffrey McDonough, President and CEO of Sobi.
Swedish Orphan Biovitrum AB (publ) (Sobi) has been awarded the Company of the Year Award at the European Mediscience Awards 2014.
Companies that have gained recognition from analysts and investors for management, financial stability and growth with a well-defined strategy to deliver its key financial, ethical and social ambitions are in contention to receive the prize.
“Sobi is truly honoured to be recognised by the Mediscience community”, said Geoffrey McDonough, President and CEO of Sobi.
The European Mediscience Awards is the largest annual gathering of private and publicly quoted healthcare, biotech and life science companies in Europe. The event recognises the importance of the capital markets to fund growth and innovation. The awards celebrate, among others, the breakthrough of the year, the best technology and the most significant contribution to the industry.
